Attana
0.059 SEK +1.72%Be the first to follow this company
Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.
Revenue
5.05M
EBIT %
-245.74 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Nordic SME
ATANA
Daily low / high price
0.057 / 0.059
SEK
Market cap
22.89M SEK
Turnover
3.79K SEK
Volume
65K
Financial calendar
General meeting
2024-05-03
Interim report
2024-05-03
Interim report
2024-08-16
Interim report
2024-11-22
Annual report
2025-02-21
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Tvaa AB (Teodor Aastrup) | 16.9 % | 16.9 % |
Arne Nabseth | 6.7 % | 6.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Teodor Aastrup återgår som VD för Attana
Attana: One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools